Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Thera...
2017年2月13日 - 11:00PM
Marketwired
Ritter Pharmaceuticals Announces Collaboration with University
of British Columbia to Explore Development of Microbiome
Therapeutics in Environmental Enteropathy
LOS ANGELES, CA-(Marketwired - Feb 13, 2017) - Ritter
Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or
the "Company"), a developer of novel therapeutic products that
modulate the human gut microbiome to treat gastrointestinal
diseases, today announced that it is collaborating with Dr. B Brett
Finlay from the Michael Smith Laboratories at the University of
British Columbia ("UBC") to study the role of the microbiome and
RP-G28 in environmental enteropathy ("EE").
As part of the collaboration, Dr. B. Brett Finlay, an
award-winning microbiologist in the fields of innate immunity and
microbiome research, plans to explore the microbiome's role in
environmental enteropathy. The pre-clinical research is designed to
build upon Dr. Finlay's previously published studies demonstrating
the gut microbiome's role in contributing to the causes of EE.
Ritter Pharmaceuticals is providing its lead compound, RP-G28, for
use in the study. RP-G28 is currently in a Phase 2b/3 study in
humans for the treatment of lactose intolerance. In previous human
studies, RP-G28 has demonstrated significant beneficial changes to
the gut microbiome that have been associated with potential to
improve a variety of digestive disorders.
Andrew J. Ritter, Co-founder and President of Ritter
Pharmaceuticals, added, "we are pleased to be collaborating with
Dr. Finlay and his team to better understand therapeutic
interventions that may reverse signs of environmental enteropathy,
a significant worldwide health issue. We're excited to apply our
clinical knowledge of RP-G28 in a way that has significant
possibilities to produce substantial social benefits in developing
countries."
Dr. B Brett Finlay, Professor in the Michael Smith Laboratories,
and the Departments of Biochemistry and Molecular Biology, and
Microbiology and Immunology at the University of British Columbia,
added, "We are pleased to be working with Ritter Pharmaceuticals to
explore potential treatments and therapies to environmental
enteropathy that affects so many of the world's children. Testing
RP-G28 in the relevant model will greatly facilitate preclinical
testing of this compound for affecting the outcome of EE."
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. (www.RitterPharma.com,
@RitterPharma) develops novel therapeutic products that modulate
the gut microbiome to treat gastrointestinal diseases. Its lead
product, RP-G28, has the potential to become the first FDA-approved
treatment for lactose intolerance, a condition that affects
millions worldwide. The company is further exploring the
functionality and discovering the therapeutic potential gut
microbiome changes may have on treating/preventing a variety of
conditions including: gastrointestinal diseases, immuno-oncology,
metabolic, and liver disease.
About the University of British Columbia
The University of British Columbia is a global centre for
research and teaching, consistently ranked among the top 20 public
universities in the world. Since 1915, UBC's entrepreneurial spirit
has embraced innovation and challenged the status quo. UBC
encourages its students, staff and faculty to challenge convention,
lead discovery and explore new ways of learning. At UBC, bold
thinking is given a place to develop into ideas that can change the
world.
Forward-Looking Statements
This release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements related to our ability to bring RP-G28 to
market. Management believes that these forward-looking statements
are reasonable as and when made. However, such statements involve a
number of known and unknown risks and uncertainties that could
cause the Company's future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to, risks
associated with the drug development process generally, including
the outcomes of planned clinical trials and the regulatory review
process. For a discussion of certain risks and uncertainties
affecting Ritter Pharmaceuticals' forward-looking statements,
please review the Company's reports filed with the Securities and
Exchange Commission, including, but not limited to, its Annual
Report on Form 10-K for the period ended December 31, 2015 and
Quarterly Reports on Form 10-Q for the periods ended March 31,
2016, June 30, 2016 and September 30, 2016. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date on which they are made. These
statements are based on management's current expectations and
Ritter Pharmaceuticals does not undertake any responsibility to
revise or update any forward-looking statements contained herein,
except as expressly required by law.
Contact Information
Contacts Ellen Mochizuki 310-203-1000 ellen@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024